Ligand buys a handful of biologics for $4M; Merck KGaA and Threshold get on the FDA fast track;

@FierceBiotech: Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma. News | Follow @FierceBiotech

@JohnCFierce: It's a great time to go shopping in Europe. Three deals in the last 24 hours, with U.S. biotechs buying into European companies. | Follow @JohnCFierce

> Merck KGaA and Threshold Pharmaceuticals ($THLD) picked up the FDA's fast-track designation for evofosfamide, in Phase III development for pancreatic cancer. More

> Ligand Pharmaceuticals ($LGND) acquired more than 15 biologics programs from Selexis for $4 million in cash, picking up assets in various stages of development. News

> Gene therapy biotech Juventas Therapeutics raised $13.5 million in equity, cash that will support the development of its lead asset as a treatment for organ injury. Item

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: FDA approves Nevro device that eliminates side effect of spinal stimulation. Article | Follow @VarunSaxena2

@EmilyWFierce: Google signs on Harvard doc to lead bioinformatics study. News | Follow @EmilyWFierce

> Autonomic raises $38M to fund U.S. pivotal trial, EU marketing for headache microstimulator. News

> FDA grants priority review status in first-line glioblastoma for Medtronic, J&J-backed startup Novocure. More

Pharma News

@FiercePharma: Teva passed up an opportunity to buy Mylan target Perrigo: Globes. Report | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

> Analysts 'skeptical' Sanofi can turn around Afrezza launch, but DTC ads are coming. News

> Biogen's hot MS meds could push Pfizer off its CNS throne. Article

> GSK chief sees cheap money spurring 'poor choices' in pharma M&A. More

Pharma Manufacturing News

> 33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme. Report

> Alexion to build $506M plant in Ireland, add 200 workers. News

> Hikma building its sterile injectable operation with Bedford equipment and products. Story

> Eisai to boost Indian API production to cut costs. Item

> Novartis' Sandoz expands Poland plant with packaging facility. Article

Pharma Asia News

> Australia negotiates pharmacy reimbursement increase as part of budget savings. Report

> Japan's Oncolys begins PhI trial of cancer drug licensed from Astellas. Item

> India eyes new manufacturing, clinical trial models to sell generics to Japan. More

> India's Punjab state goes its own way on drug price caps. Story

> Takeda, Orexigen end CV study for obesity drug Contrave. Article

Drug Delivery News

> Researchers turn to bacteria secretion systems to deliver proteins. Report

> Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. More

> Supercooled nanoparticles offer targeted delivery approach. Story

> Gene editing player gets $25M in Series A round. Item

> Neuroderm stock up as FDA lifts hold on its subcutaneously delivered Parkinson's candidate. Article

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.